Neoadjuvant immunotherapy could considerably improve long-term outcomes and quality of life for patients with desmoplastic melanoma, according to prospective study results.Nearly three-quarters of ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...
Organ preservation may be a viable option for select patients with locally advanced rectal cancer, according to the first results of the NO-CUT trial. The study investigated the efficacy of total ...
A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a subset of head and neck cancer known as oropharyngeal cancer. A rare ...
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO ...
Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in perioperative setting in resectable non-small cell lung cancer Broad EU label with nine approved indications in solid ...
Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 ...
Nisha Mohindra, MD, and Christopher Towe, MD, discuss what early-stage non-small cell lung cancer treatment options have looked like in the past and a more recent treatment option, neoadjuvant therapy ...
The surgical outcomes of colon cancer vary with its anatomical location. Neoadjuvant chemotherapy can aid in improving the postsurgical outcomes of both right and left colon cancer, decreasing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results